Board of Directors

Arie Belldegrun, M.D., FACS

Chairman, President &
Chief Executive Officer

Dr. Belldegrun has been a leader in developing novel cancer treatments and closely involved with the founding and advancement of several successful private and public biopharmaceutical companies. In 1996, he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman and as a board member until 2007, when it was acquired by Astellas Pharma Inc. From 2003 to 2009, he was the founding Vice-Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology, Inc., until it was acquired by Johnson & Johnson. Dr. Belldegrun is the Chairman of Arno Therapeutics, Inc., Two River Group, and UroGen Pharma, Ltd. (formerly TheraCoat, Ltd.) and currently serves as a board member of Cell Design Labs. He is also a member of the Parker Institute for Cancer Immunotherapy’s Strategic Advisory Group. In addition, at the University of California, Los Angeles (UCLA), Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine. Prior to joining UCLA, he was a research fellow in surgical oncology and immunotherapy at the National Cancer Institute/NIH, working under Dr. Steven A. Rosenberg. Dr. Belldegrun earned his M.D. at the Hebrew University Hadassah Medical School in Jerusalem. He undertook his postgraduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at the Brigham and Women’s Hospital and Harvard Medical School in Boston, MA. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.

David Bonderman

Lead Independent Director

Mr. Bonderman has served as a member of the board since February 2011 and as lead independent director of the board since June 2014. Mr. Bonderman is a founding partner of TPG, one of the world’s largest private equity investment firms. Through its global buyout platform, TPG generally makes significant investments in operating companies through acquisitions and restructurings across a broad range of industries globally. Mr. Bonderman serves or has served on the board of directors of several public companies, including: Armstrong World Industries, Inc.; Burger King Holdings, Inc.; Continental Airlines, Inc., CoStar Group, Inc.; Ducati Motor Holdings S.p.A.; General Motors Company; Gemalto N. V.; Gemplus International S.A. (predecessor to Gemalto); and Ryan Air Holdings, plc, of which he is chairman. Mr. Bonderman also serves or has served on the board of directors of several private companies, including: IASIS Healthcare, LLC; Univision Communications, Inc.; XOJET, Inc.; and UBER Technologies, Inc. Prior to forming TPG in 1992, Mr. Bonderman was chief operating officer of the Robert M. Bass Group, Inc. (RMBG), now d/b/a Keystone Group, L.P. in Fort Worth, Texas. Prior to joining RMBG in 1983, Mr. Bonderman was a partner in the law firm of Arnold & Porter in Washington, D.C., where he specialized in corporate, securities, bankruptcy and antitrust litigation. From 1969 to 1970, Mr. Bonderman was a Fellow in Foreign and Comparative Law in conjunction with Harvard University, and from 1968 to 1969, he was Special Assistant to the U.S. Attorney General in the Civil Rights Division. From 1967 to 1968, Mr. Bonderman was assistant professor at Tulane University School of Law in New Orleans. Mr. Bonderman graduated magna cum laude from Harvard Law School in 1966. He was a member of the Harvard Law Review and a Sheldon Fellow. He is a 1963 graduate of the University of Washington in Seattle.

Farah Champsi

Ms. Champsi has served as a member of the board since May 2013. She has served as a managing director at InterWest Partners, a venture capital firm, since May 2015 and at Alta Partners, a venture capital firm, since 2000. From December 2012 to April 2017, Ms. Champsi served on the board of directors of Allakos, Inc., a biotechnology company. From January 2008 to December 2014, Ms. Champsi served on the board of directors of Trevena, Inc., a publicly reporting biopharmaceutical company. From July 2010 to June 2014, Ms. Champsi served on the board of directors of Chimerix, Inc., a publicly reporting biopharmaceutical company. From October 2005 to May 2013, Ms. Champsi served on the board of directors of Portola Pharmaceuticals, Inc. From 1987 to 1999, Ms. Champsi held various positions at Robertson Stephens & Company, LLC, an investment banking firm, including managing director from 1992 to 1999 and head of the global life sciences investment banking group from 1995 to 1999. Ms. Champsi holds an M.B.A. degree from the Stanford University Graduate School of Business and a B.A. in Economics from Smith College.

Ian Clark

Mr. Clark has served as a member of the board since January 2017. Mr. Clark most recently served as the chief executive officer and Head of North American Commercial Operations at Genentech from 2010 to 2016. He joined Genentech in 2003 as senior vice president and general manager, BioOncology. In August 2005, he was named senior vice president, Commercial Operations. In January 2006, Mr. Clark was named Executive Vice President, Commercial Operations, and became a member of the Executive Committee. Mr. Clark was named head of Global Product Strategy and chief marketing officer of Roche in April 2009. Prior to joining Genentech, Mr. Clark served as general manager of Novartis Canada, overseeing all of the company’s country operations, and as Chief Operating Officer for Novartis United Kingdom. Mr. Clark worked in executive positions in sales and marketing for Sanofi and Ivax in the United Kingdom, France and Eastern Europe. Mr. Clark began his career at Searle, where he held management positions in both sales and marketing. Since January 2017, Mr. Clark has served on the boards of Agios Pharmaceuticals, Inc., a public biopharmaceutical company, Corvus Pharmaceuticals, Inc., a public biopharmaceutical company, and Shire plc, a public biotech company. He has served on the board of directors of the Biotechnology Industry Organization (BIO) since 2009 as well as on the boards of TerraVia and the Gladstone Foundation and as a member of the Federal Reserve Bank of San Francisco’s Economic Advisory Council. Mr. Clark received a bachelor of science degree and honorary doctorate in Biological Sciences from Southampton University in the United Kingdom.

Roy Doumani

Roy Doumani is a professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Executive Director of the UCLA Business of Science Center. He serves as Co-Chairman of the Zhejiang California NanoSystems Institute in the People’s Republic of China (PRC) and is a shareholder and Director of the first joint venture bank in the PRC, Xiamen International Bank. Mr. Doumani has been involved with numerous financial institutions: Director of First Los Angeles Bank, Chairman of First Interstate Bank of Hawaii, Chairman of World Trade Bank in Los Angeles, Executive Director of HonFed Bank, and one of the Founders of Agensys, Inc. He is presently Chairman of Neural Analytics. Mr. Doumani graduated from UCLA with a degree in Business and Finance and received a law degree from the University of Southern California.

Franz Humer

Dr. Humer is chairman of the board of directors of the International Centre for Missing & Exploited Children and chairman of the Humer Foundation. He is also an independent director of Citigroup Inc. (since 2012), and Chugai Pharmaceuticals Ltd. (Japan). Dr. Humer also serves as a director of Bial Pharmaceuticals (Portugal), WISeKey (Cyber Security Company, Switzerland), and as a member of the International Advisory Board of Allianz SE. He served as chairman of Diageo plc from 2008 to 2017. In addition, Dr. Humer served as head of pharmaceuticals and then as chief operating officer of F. Hoffmann-La Roche Ltd. (1996-1998), prior to serving as chief executive officer of Roche Group (1998-2001) and later as chairman and chief executive officer (2001-2008). His tenure as chairman of Roche Holding Ltd. extended from 2008 to 2014. Before joining Roche Group, he served on the board of Glaxo Holdings plc and progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-US operations for 13 years. In 1973, Dr. Humer joined Schering Plough Corporation where he held various general management positions in Latin America and Europe. Dr. Humer attended the University of Innsbruck, where he earned a Ph.D. in Law. He went on to earn an M.B.A. at INSEAD in Fontainebleau.

Joshua A. Kazam

Mr. Kazam is one of Kite’s founders and has served as a member of the board since its inception in June 2009. Mr. Kazam also served as our president through September 2010. In June 2009, Mr. Kazam co-founded Two River Consulting, LLC, a life-science consulting and investment firm. Since October 2005, he has also served as an officer and director and is the co-owner of Riverbank Capital Securities, Inc., a FINRA member broker-dealer. From 2002 to 2004, Mr. Kazam served as the director of Investment Management for the Orion Biomedical Fund, a private equity fund focused on biotechnology investments. Since 2005, Mr. Kazam has served on the board of directors of Capricor Therapeutics, Inc., a publicly reporting biotechnology company. Mr. Kazam served on the board of directors of Velcera, Inc., from 2003 until it was acquired by Perrigo Company plc in 2013. Mr. Kazam has served on the board of directors of MedPod, Inc., since August 2015. He is also the co-founder and has served on the board of directors of Veterinary Prime, Inc. since its inception in February 2015. Mr. Kazam has also served on the board of directors of Hubble Contacts since May 2016. Mr. Kazam received his degree in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and is a member of the Wharton School’s Undergraduate Executive Board.

Ran Nussbaum

Ran is a managing partner and co-founder of The Pontifax Group. The fund is running more than 45 portfolio companies all around the globe. Prior to joining Pontifax, he was a partner at Israel’s largest business intelligence and strategic consulting firm. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Ran serves as a board member on many of Pontifax’s portfolio companies, including Keros (as chairman), UroGen, cCAM Biotherapeutics (bought by Merck), Eloxx Pharmaceuticals, Nutrinia Ltd, Novellus Ltd, Quiet Therapeutics and other bio-pharma companies. He also chaired Ocon Medical, NasVax and ran Biomedix Ltd and Spearhead Ltd in the past.

Jon Peacock

Jon Peacock is the chairman of Arix Bioscience. He was chief financial officer of Amgen from 2010 to 2014. In this role, he was responsible for finance, investor relations, strategy, corporate development and procurement. Prior to Amgen, Mr. Peacock served as chief financial and administration officer for Novartis Pharmaceutical AG beginning in 2005. He oversaw finance, strategic planning, mergers and acquisitions, IT and procurement. In addition, Mr. Peacock was responsible for Novartis’ malaria elimination program, a corporate citizenship initiative in conjunction with the major donor organizations that supplied the company’s malaria medicine at cost to countries throughout Africa. Previously, Mr. Peacock was a partner at McKinsey and Company, working for the consulting firm’s Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. Mr. Peacock has an MA degree in economics from the University of St. Andrews in Scotland and is a chartered accountant.

Steven B. Ruchefsky

Mr. Ruchefsky has served as a member of the board since February 2011. Mr. Ruchefsky has been a private investor, both as principal and as investment manager, since 2000. During this period, Mr. Ruchefsky was responsible for the initial funding of many successful businesses and ventures, including Cougar Biotechnology Inc., later acquired by Johnson & Johnson, and Ziopharm Oncology Inc. He serves on the boards of several other public and private companies, including Arno Therapeutics Inc. (since September 2010), MD Solar Sciences (since April 2010) and Energy Pioneer Solutions (since June 2012). Mr. Ruchefsky began his career at the New York City law firm, Morrison Cohen, where he became a partner, member of management and chair of a specialized litigation group. Upon leaving Morrison Cohen, Mr. Ruchefsky was a principal of an early-stage venture capital operation. Mr. Ruchefsky is a graduate of The George Washington University Law School.

Owen N. Witte, M.D.


Dr. Witte received his undergraduate degree from Cornell and his MD from Stanford University. He completed postdoctoral research at MIT, then joined the faculty at UCLA. Dr. Witte is serving at UCLA where he was appointed a University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Dr. Witte is also a professor of microbiology, immunology and molecular genetics, the UCLA David Saxon Presidential Chair in Developmental Immunology. He is the Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Dr. Witte has made significant contributions to the understanding of human leukemias, immune disorders, and epithelial cancer stem cells. His work includes the discovery of tyrosine kinase activity for the ABL gene and the demonstration of the BCR-ABL oncoproteins in human leukemias. This has had practical impact in leading to the development of kinase-targeted therapy as an effective treatment for these leukemias and other cancers. His work also led to the co-discovery of Bruton’s tyrosine kinase (“BTK”), which is required for normal B-lymphocyte development and, when mutated, leads to X-linked agammaglobulinemia, a form of immune deficiency. New inhibitors for BTK are entering clinical practice for the treatment of certain lymphomas and leukemias. Recent work has concentrated on defining the stem cells for epithelial cancers of the prostate and other organ sites to help define new types of therapy for these diseases. His work utilizes advanced whole body imaging techniques, such as positron emission tomography to monitor cancer growth and cellular immune functions. Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. Recognition for his research includes the Milken Foundation Award in Basic Cancer Research, the Rosenthal Award of the American Association for Cancer Research, the Dameshek Prize of the American Society of Hematology, the Alpert Foundation Prize, the Leukemia & Lymphoma Society’s de Villiers International Achievement Award, the UCLA Faculty Research Lecture, the Nakahara Memorial Lecture Prize, and the AACR G.H.A. Clowes Memorial Award. Dr. Witte currently serves on several editorial and advisory boards, and he previously served on the Board of Directors for the American Association for Cancer Research. He was recently appointed by President Obama to the President’s Cancer Panel.